Plain-English translation of NCT07418736 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called CM326, which is a type of antibody designed to reduce inflammation in the lungs. Researchers want to see if CM326 can improve breathing and reduce flare-ups in people with moderate to severe COPD. About half of participants will receive the medication, and half will receive a placebo (a fake injection) so researchers can fairly compare how well the treatment works.
COPD is a serious lung disease that makes it hard to breathe, and current treatments don't help everyone equally. This trial is testing whether this new medication can provide better relief and prevent the sudden worsening episodes (called exacerbations) that people with COPD often experience.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic multiple times over about 6 to 14 months. During the screening period, you'll have tests to confirm you're eligible. Then you'll be randomly assigned to receive either the medication or a placebo by injection under your skin every few weeks, and you'll have regular check-ups to track how you're doing. After the treatment period ends, you'll have a 12-week follow-up period with additional safety visits.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China